Yarra River
Search
Skip Navigation Links
Home
About VESKI
VESKI Standard
VESKI Board
VESKI Design Sub-Committees
Support VESKI
VESKI Fellowships
VESKI Innovation Fellowship (Australian)
VESKI Innovation Fellowships (Non-Australian)
VESKI Fellows
VESKI Awards
VESKI International Connections
VESKI Entrepreneur in Residence
Media Downloads
VESKI in the Community
Lectures/Conferences
Exhibitions
Workshops/Symposiums
Boardroom Luncheons
News & Events
Our Supporters


Advance Global Australian Professionals

VESKI Fellows
Ass/Prof Ygal Haupt

Associate Professor Ygal Haupt returned from the Hebrew University Hadassah Medical Jerusalem to head up a new laboratory in Tumour Suppressor Biology at the Peter MacCallum Cancer Centre.  

Associate Professor Haupt was awarded a VESKI Innovation Fellowship in February 2009.

Research Project Title: Regulation of Tumour Suppression

Research Project Description:The most important agent of the body for fighting cancer is the cellular protein p53. It plays a key role in responding to assaults that damage DNA. Upon activation, p53 acts to eliminate cells of cancerous potential by halting their growth. In more than 50% of all human cancers, it loses its anticancer properties through mutation. In an insidious manner, mutation of p53 not only robs it of its ability to prevent cancer, but also confers it with new cancer promoting capacity. To better treat cancer we need to understand how both normal p53 and mutant p53 are controlled. Detailed dissection of the regulatory mechanisms of both forms of p53 is allowing us to identify new potential therapeutic anticancer targets.

A key partner of both normal and mutant p53 is the promyelocytic protein, PML. We have recently identified an important mechanism by which PML levels are controlled. We intend to explore the implications of this regulation further and examine how it influences p53. Human cancers will be screened for the involvement of these proteins, to gain new insights into cancer onset. We intend to identify small molecules that are able to control the levels of these anti-cancer agents through a high throughput screen and translate this knowledge to the clinic. The intended practical outcome of these studies is to aid cancer diagnosis and provide new anti-cancer drugs.

Please click here to view Media Release of Associate Professor Ygal Haupt's Announcement as a VESKI Innovation Fellow.

To read Associate Professor Haupt's expanded profile and research description please click here.

- Return to Fellows -

NEWSLETTERS
Click here to subscribe to the VESKI Newsletter.
MEMBER LOGIN
Username
Password
Forgot Password?
LATEST NEWS
VESKI Fellowship Applications have NOW CLOSED
VESKI's International Connections Program
L’Oréal Australia 2010 Fellows Announced
CURRENT EVENTS
RMIT Business Lecture Series - Sept
Dr Jonathan Rosen - Lecture
All-Energy Australia 2010
The Third Knowledge Cities World Summit